VivoSim Labs Shares Rise 82% Following Seven-Figure Pharmaceutical Partnership
VivoSim Labs (VIVS) experienced a significant premarket surge of over 82%, with its stock price reaching $0.22. The rally follows the announcement of a multi-million dollar agreement with a top-10 global pharmaceutical company. The partnership focuses on utilizing VivoSim's NAMkind human cell technology to conduct liver and intestinal toxicity testing. This deal represents a major commercial milestone for the company, validating its specialized cellular testing platform within the large-scale pharmaceutical industry.
